Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Durable responses with anti-BCMA CAR T-cell for multiple myeloma

Publish date:: December 6, 2020

Key clinical point: Cilta-cel was associated with rapid, deep, and durable responses in patients with heavily pretreated multiple myeloma.Major finding: The overall response rate was 96.9%, with most responses VGPR or better.

Study details: Prospective phase 1b/2 trial in 97 patients with relapsed/refractory multiple myeloma.

Disclosures: The study was sponsored by Janssen Research & Development and Legend Biotech. Dr. Madduri disclosed honoraria, consultancy, and speakers bureau activities for those companies and others.

Citation:

Madduri D et al. ASH 2020. Abstract 177.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lymphoma & Plasma Cell Disorders

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,